Circulating enterolactone and risk of breast cancer: a prospective study in new york

ABSTRACT It has been proposed that phyto-oestrogens protect against breast cancer. Lignans are the main class of phyto-oestrogens in Western diets. We conducted a case–control study of

breast cancer and serum levels of the main human lignan, enterolactone, nested within a prospective cohort study, the New York University Women's Health Study. Serum samples collected

at enrollment and stored at −80°C were used. Among 14 275 participants, 417 incident breast cancer cases were diagnosed a median of 5.1 years after enrollment. Cohort members individually

matched to the cases on age, menopausal status at enrollment, serum storage duration and, if premenopausal, day of menstrual cycle were selected as controls. No difference in serum

enterolactone was observed between postmenopausal cases (median, 14.3 nmol l−1) and controls (14.5 nmol l−1), whereas premenopausal cases had higher levels (13.9 nmol l−1) than their matched

controls (10.9 nmol l−1, _P_-value=0.01). In the latter group, the odds ratio for the highest _vs_ the lowest quintile of enterolactone was 1.7 (95% confidence interval (CI), 0.8–3.4;

_P_-value for trend=0.05) and after adjustment for known risk factors for breast cancer was 1.6 (95% CI, 0.7–3.4; _P_-value for trend=0.13). We observed a moderate positive correlation

between serum enterolactone and serum sex hormone-binding globulin in postmenopausal women (_r_=0.29 in controls (_P_<0.001) and _r_=0.14 in cases (_P_=0.04)), but no correlation with

oestrogens or androgens. These results do not support a protective role of circulating lignans, in the range of levels observed, in the development of breast cancer. SIMILAR CONTENT BEING

VIEWED BY OTHERS URINARY EQUOL LEVELS ARE POSITIVELY ASSOCIATED WITH URINARY ESTRADIOL EXCRETION IN WOMEN Article Open access 30 September 2021 DIETARY INTAKE OF ISOFLAVONES AND COUMESTROL

AND RISK OF PANCREATIC CANCER IN THE PROSTATE, LUNG, COLORECTAL, AND OVARIAN CANCER SCREENING TRIAL Article 16 December 2024 LIPOPROTEIN AND METABOLITE ASSOCIATIONS TO BREAST CANCER RISK IN

THE HUNT2 STUDY Article 04 August 2022 MAIN It has been suggested that phyto-oestrogens protect against hormone-dependent cancers, in particular breast cancer, through their weak

agonist/antagonist oestrogen properties as well as their actions on oestrogen synthesis and bioavailability (Setchell et al, 1981; Adlercreutz et al, 1982; Adlercreutz, 1990; Rose, 1992). In

addition, phyto-oestrogens have been reported to have antioxidant and antiproliferative properties which provide additional pathways through which they may reduce cancer risk (Adlercreutz

and Mazur, 1997; Kurzer and Xu, 1997). The two main groups of phyto-oestrogens found in humans, the isoflavonoids and the lignans, are formed in the intestinal tract by transformation of

plant precursors (isoflavone glycosides and plant lignans) by the microflora. Soy and soy products are the main sources of isoflavones, whereas lignans are found in oilseeds, in particular

flaxseed, whole-grain products, nuts, berries, legumes, and some vegetables and fruits (Thompson et al, 1991; Adlercreutz and Mazur, 1997; Mazur, 1998; Horn-Ross et al, 2000). A number of

studies have focused on isoflavones and examined the association of intake of soy or soy protein with breast cancer risk, mostly in Asian populations (Peeters et al, 2003). Research on the

association between the dietary intake of specific phyto-oestrogens, in particular lignans, and disease risk has been hampered, though, by the paucity of data on the amount of these

compounds in individual foods, although the development of appropriate databases is underway (Horn-Ross et al, 2000; Kiely et al, 2003; Valsta et al, 2003). Dietary intake of foods known to

be rich in lignan precursors has been shown to correlate positively with lignan plasma levels (Horner et al, 2002). Lignan intake, assessed by a 24-h dietary recall, also correlated

positively with serum enterolactone (Kilkkinen et al, 2003), thus suggesting that levels of circulating enterolactone may provide a useful alternative approach to dietary questionnaires when

assessing the effect of lignans on disease risk. The association between circulating levels of the main lignan enterolactone and breast cancer risk was assessed in a case–control study

nested within the New York University (NYU) Women's Health Study, a prospective cohort study of cancer, hormones, and environmental factors. The study focused exclusively on

enterolactone based on the results of a preliminary study that examined the distribution and long-term reliability of serum measurements of the two main lignans, enterolactone and

enterodiol, and of a number of isoflavonoid phyto-oestrogens. With the exception of enterolactone, phyto-oestrogen concentrations were below the detection limits for a large proportion of

subjects, and the temporal reliability coefficients were low, indicating that our cohort was not well suited to study the effect of these compounds on disease risk (Zeleniuch-Jacquotte et

al, 1998). As some of the mechanisms of action suggested for a protective effect of lignans are related to oestrogen synthesis and bioavailability, we also examined the correlation of serum

enterolactone with circulating sex hormones and sex hormone-binding globulin (SHBG) in the group of postmenopausal women for whom these measurements were available (Zeleniuch-Jacquotte et

al, 2004). MATERIALS AND METHODS THE NYU WOMEN'S HEALTH STUDY COHORT Between 1985 and 1991, the NYU Women's Health Study enrolled 14 275 healthy women aged 34–65 years at the

Guttman Breast Diagnostic Institute, a breast cancer screening centre in New York City (Toniolo et al, 1991; Toniolo et al, 1995). Women who had been pregnant or taken hormonal medications

in the 6 months preceding their visit were not eligible. At the time of enrollment, women were classified as postmenopausal if they reported no menstrual cycles in the previous 6 months, a

total bilateral oophorectomy, or a hysterectomy without total oophorectomy prior to natural menopause and their age was 52 years or older. A total of 7054 participants (49.4%) were

postmenopausal. After written informed consent was obtained, demographic, medical, anthropometric and reproductive data were collected through self-administered questionnaires. Dietary data

were collected using a semiquantitative food frequency questionnaire based on the Block questionnaire used in NHANES II (Block et al, 1986, 1990). In total, 30 ml of non-fasting peripheral

venous blood were drawn prior to breast examination. After blood drawing, tubes were kept covered at room temperature (21–25°C) for 15 min, then at 4°C for 60 min to allow clot retraction,

and then centrifuged for 25 min. After centrifugation, serum samples were divided into 1 ml aliquots and immediately stored at −80°C for subsequent biochemical analyses. Up to 1991, women

who returned for annual breast cancer screening were invited to contribute additional blood donations. Data on the use of oral contraceptives and hormone replacement therapy were collected

in follow-up questionnaires mailed to participants in 1995 and in 1998. NESTED CASE–CONTROL STUDY OF BREAST CANCER The current study was based on an ongoing case–control study of sex

hormones and breast cancer. Cases were identified through active follow-up of the cohort by mailed questionnaires approximately every 2–4 years and telephone interviews for nonrespondents,

as well as record linkage with state cancer registries in New York, New Jersey and Florida, and with the US National Death Index. A capture–recapture analysis estimated the ascertainment

rate in our cohort to be 95% (Kato et al, 1999). Only incident cases (ie diagnosed at least 6 months after blood donation) of invasive breast cancer were included. Medical and pathology

reports were requested to confirm the diagnosis. Controls were selected at random among appropriate risk sets. The risk set for a case consisted of all women who were alive and free of

cancer at the time of diagnosis of the case and who matched the case on menopausal status at the time of enrollment, age at entry (±6 months), date of enrollment (±3 months), and if

premenopausal, day of menstrual cycle at the time of blood donation. For the present study of enterolactone and breast cancer, one control was selected at random between the two controls (or

four for premenopausal women) selected for the study of sex hormones in order to limit study costs. In addition, the following exclusion criteria were applied to both cases and controls:

(1) use of antibiotics in the 4 weeks preceding blood donation because such use has been shown to almost completely eliminate the formation of enterolactone from plant precursors in the gut

(Borriello et al, 1985; Adlercreutz et al, 1986; Kilkkinen et al, 2002); (2) diagnosis with other cancer or cardiovascular disease in order to preserve the serum samples of these

participants for the study of these diseases. LABORATORY ANALYSES Enterolactone was measured by time-resolved fluoroimmunoassay (Adlercreutz et al, 1998) with slight modifications (Stumpf et

al, 2001). For the recovery calculation, 15 _μ_l of 3H-oestradiol glucuronide (enterolactone glucuronide is not available) was added to the tubes containing 200 _μ_l of plasma and

equilibrated for 30 min at room temperature. Then, 200 _μ_l of acetate buffer 0.1 M pH 5.0 containing 2 U ml−1 sulphatase and 0.2 U ml−1 _β_-glucuronidase were added. After mixing, the tubes

were incubated overnight at 37°C. After hydrolysis, the free enterolactone was extracted twice with 1.5 ml of ethyl ether. The separation of the phases was carried out by freezing the water

phase. After evaporation of the ether, 200 _μ_l of the TR-FIA assay buffer was added and a 20 _μ_l aliquot taken for calculation of recovery and two 20 _μ_l aliquots used for the time

resolved fluoroimmunoassay. Samples from a case and her matched control were always assayed in the same batch. The laboratory analyses were performed blind, and all of the batches were

analysed with two quality control samples used throughout the whole procedure, and three samples used for the immunoassay step only. Two samples from a common pool that were labelled to

preclude their identification were interspersed every 11 matched sets to assess the laboratory precision. The mean of the within-batch coefficient of variation for the seven batches was

8.9%. STATISTICAL METHODS Enterolactone measurements were log-transformed to reduce departure from the normal distribution. To test for differences in enterolactone levels (and other

continuous variables) between case and control subjects, we used a mixed-effects regression model to take into account the matched design (Liang and Zeger, 1986). _P_-values to compare

proportions between case and control subjects were generated using the conditional logistic regression model. To compute odds ratios (ORs), serum measurements were categorised into quintiles

separately for pre- and postmenopausal subjects, using the frequency distribution of the cases and the controls combined. The data were analysed using conditional logistic regression

(Breslow and Day, 1980). Odds ratios were computed relative to the lowest quintile. Likelihood ratio tests were used to assess the significance of overall associations, linear trends and

deviations from linearity. Reported trend test _P_-values correspond to enterolactone variables treated as ordered categorical variables. Analyses were also performed on the continuous

variables. Analyses were conducted using the SAS Release 8.02 and EGRET statistical packages. All _P_-values are two-sided. RESULTS A total of 461 incident breast cancer cases diagnosed

prior to 1 January 1995 had been identified by the start date of the study, 1 September 1998. A total of 38 cases were excluded from the present study for the following reasons: diagnosis of

other cancer prior or subsequent to diagnosis (_n_=24), diagnosis of coronary heart disease (_n_=3), and use of antibiotics in the 4 weeks prior to study enrollment (_n_=11). Six additional

cases were excluded because the volume of serum was insufficient for the assay. As a result, 417 cases are included in this report. Nine participants became cases after being selected as

controls and are included both as cases and controls in the appropriate matched sets (Robins et al., 1986). Pathology reports were obtained for 349 cases (84%) and the diagnoses of 59

additional cases (14%) were confirmed through Tumour Registries. Table 1 presents the characteristics of the study subjects by menopausal status. The median age at blood donation was 44

years in premenopausal women, and 59 years in postmenopausal women, and the overall median lagtime between blood donation and diagnosis was 5.1 years (range, 6 months to 9.5 years). Overall,

the proportion of nulliparous women was higher among cases (31%) than among controls (25%, _P_=0.05). Although no longer statistically significant, this difference was observed in both pre-

and postmenopausal women. Among women premenopausal at blood donation, cases tended to be older at first full-term pregnancy (_P_=0.08), reported more often a family history of breast

cancer (_P_=0.001) and were less likely to have used hormone replacement therapy than controls (_P_=0.05). Among postmenopausal women, cases tended to have a higher weight (_P_=0.01) and

body mass index (_P_=0.09) than controls. Table 2 reports serum levels of enterolactone. Overall, levels were higher in cases (median, 14.3 nmol l−1) than in controls (12.8 nmol l−1,

_P_=0.04). When levels were examined according to menopausal status, no difference was observed between postmenopausal cases and controls, whereas premenopausal cases had higher levels

(median, 13.9 nmol l−1) than their matched controls (10.9 nmol l−1, _P_=0.01). Table 3 reports ORs for breast cancer associated with quintiles of enterolactone in premenopausal women. In the

conditional model controlling only for matching factors, a trend of increasing risk with increasing level of enterolactone was observed (_P_=0.05). The OR was 1.7 (95% CI, 0.8–3.4) in the

highest quintile, which was slightly reduced to 1.6 (0.7–3.4) after adjusting for the following known risk factors: age at menarche, family history of breast cancer, parity, age at first

full time pregnancy, height and body mass index (_P_ for trend=0.13). Adjusting further for use of oral contraceptives and hormone replacement therapy did not materially affect the OR but

reduced the number of matched sets available for analysis to 139 (74% of total) and are therefore not presented. Similar results were obtained when log-transformed enterolactone was used on

the continuous scale. Table 4 shows the results among postmenopausal women. No association of serum enterolactone with breast cancer risk was observed in this group. There was no evidence of

correlation between enterolactone and oestrogens or androgens: all correlation coefficients were less than 0.10 (Table 5). However, we observed a positive correlation between enterolactone

and SHBG, which was stronger in controls (0.29, _P_<0.001) than in cases (0.14, _P_=0.04). This positive correlation persisted after adjusting for body mass index, a strong predictor of

circulating SHBG: the partial correlation coefficients were 0.26 (_P_<0.001) in controls and 0.13 in cases (_P_=0.09). DISCUSSION Contrary to our hypothesis, we did not observe an inverse

association between serum levels of enterolactone and risk of breast cancer. With 417 cases, the study had 80% power to detect an odds ratio of 0.59 in the highest _vs_ the lowest quartile,

that is, a 41% reduction in risk. Although we cannot rule out an association of smaller magnitude, we believe that the lack of inverse association between enterolactone and breast cancer

risk in our study is not due to lack of statistical power because of the absence of any trend among postmenopausal women and the marginally significant positive trend observed among

premenopausal women. We also considered whether error in exposure measurement could explain these results, since enterolactone was measured at a single point in time whereas the true

exposure of interest is long-term average concentration of enterolactone. However, in a preliminary study we have shown that, in our cohort subjects, circulating enterolactone is fairly

stable over a 2-year period of time, as indicated by a reliability coefficient of 0.55 (Zeleniuch-Jacquotte et al, 1998). In addition, because the study was based on serum samples obtained

prior to diagnosis of disease, the error in measurement would be expected to be nondifferential with respect to case–control status and therefore very unlikely to result in a change of

direction of the exposure–disease association in premenopausal women (Kelsey et al, 1996). Antibiotic use, through its action on the microflora of the gut, greatly reduces circulating levels

of enterolactone (Kilkkinen et al, 2002). Women who reported taking antibiotics in the 4 weeks preceding blood donation were excluded, but recent data show that serum enterolactone

concentrations could be significantly lower among subjects who use oral antimicrobials up to 12–16 months before serum sampling, as compared to nonusers (Kilkkinen et al, 2002). Some women,

both among cases and controls, with usually high serum enterolactone levels may have been misclassified as having low levels if they had taken antibiotics in the 1–16 months prior to

enrollment. However, it is again very unlikely that such misclassification would result in a spurious positive association among premenopausal women since we used prediagnostic sera. Few

studies have been published to date on the association between biological levels of lignans and breast cancer risk. Three studies reported on the urinary excretion of phyto-oestrogens

including lignans. In an individually matched case–control study in Western Australia (144 cases), Ingram et al (1997) reported a significant trend of reduced risk with increasing urinary

excretion levels of both equol and enterolactone. Results were not presented separately for pre- and postmenopausal women, but the authors noted that similar trends were observed within each

group. A population-based case–control study among Chinese women in Shanghai (250 cases) reported a reduced risk with increasing urinary excretion of total isoflavonoids and total lignans,

which was present in both pre- and postmenopausal women, although stronger in premenopausal women (Dai et al, 2002). The only prospective study that examined urinary phyto-oestrogen

excretion was a case–control study (88 cases and 268 controls) nested within a cohort of postmenopausal Dutch women participating in a breast cancer screening study (den Tonkelaar et al,

2001). Elevated urinary genistein was weakly and nonsignificantly associated with a risk reduction, whereas elevated urinary enterolactone was weakly and nonsignificantly associated with

increased risk. Three studies have reported on the association of circulating levels of lignans with breast cancer risk. A population-based case–control study examined serum levels of

enterolactone in 194 cases and 208 controls in Eastern Finland (Pietinen et al, 2001). A significant inverse association with risk was observed. Results were similar in pre- and

postmenopausal women. In a case–control study nested in three population-based cohorts in northern Sweden, there was no significant association of breast cancer risk with serum enterolactone

but further analyses showed a U-shaped relationship with an increase in risk at both very low (<5.5 nmol l−1), and very high (>39.1 nmol l−1) concentrations (Hultén et al, 2002).

Analyses stratifying by cohort showed that the increase in risk with high levels of enterolactone was observed in the two cohorts with only incident cases and a high proportion of

premenopausal women (54%), whereas in the third cohort consisting mostly of older women (85% postmenopausal) from a mammary screening project with mostly prevalent cases, a slight,

nonsignificant reduction in risk was observed with high plasma enterolactone levels. Another nested case–control study, conducted in Finland, showed no association, overall or within

menopausal groups (Kilkkinen et al, 2004). It is noteworthy that all three retrospective case–control studies (Ingram et al, 1997; Pietinen et al, 2001; Dai et al, 2002) reported an inverse

association of enterolactone with risk, whereas three of the prospective studies reported no or weak positive associations and one reported a U-shaped association with risk. It is unlikely

that the results from the case–control studies could be explained by qualitative dietary modifications of the cases because one would expect that women changing their diet in response to

suspicion or diagnosis of breast cancer would switch to ‘healthy diets’ usually associated with increased enterolactone intake. However, whereas controls contributed biological samples at

their convenience, collection of samples from cases occurred before admission to hospital for surgery (Ingram et al, 1997), the morning of, or 1–2 days before surgery (Dai et al, 2002), or

at a referral clinical examination for breast symptom or suspected breast lump (Pietinen et al, 2001). It is thus possible that cases, in these stressful circumstances, reduced their overall

intake of food, including their intake of lignan-rich foods, resulting in lower circulating or urinary enterolactone levels. In addition, in two of the studies, it is possible that control

subjects who agreed to participate were self-selected for health-conscious behaviors, including eating a healthy diet rich in lignan precursors: the control participation rate was 72% in the

Finnish study (Pietinen et al, 2001) and 33% in the Australian study (Ingram et al, 1997). Studies quantifying the intakes of specific phyto-oestrogens using a food frequency questionnaire

and a nutrient database may shed additional light on the role of these compounds. Only one such study has been published to date in relation to breast cancer. The study was a case–control

study in the San Francisco Bay Area that included 1326 cases and 1657 controls from various non-Asian ethnic backgrounds (Horn-Ross et al, 2001). Intake of total phyto-oestrogens was not

associated with altered risk, including in analyses stratified by menopausal status or ethnic group. Analyses by intake of seven specific phyto-oestrogenic compounds, including lignans

(matairesinol, secoisolariciresinol, and total lignans) were also negative. Enterolactone at plasma levels that could easily be achieved in humans (400 nmol l−1) has been shown to inhibit

both formation and growth of breast tumours in rats (Saarinen et al, 2002). The mechanisms that have been suggested for a protective role of lignans against breast cancer include antioxidant

effects (Kitts et al, 1999), competitive binding with oestrogen receptors (Martin et al, 1978; Adlercreutz et al, 1992) and oestrogen synthesis and bioavailability (Adlercreutz, 1998). In

cell culture systems, enterolactone has been shown to be a moderate inhibitor of aromatase, which is involved in the peripheral conversion of androgens to oestrogens in postmenopausal women

(Adlercreutz et al, 1993; Wang et al, 1994). However, we did not observe an association between circulating enterolactone and oestrogens in our study. Lignans have also been shown to

stimulate SHBG synthesis in the liver (Adlercreutz et al, 1987, 1992). Adlercreutz et al (1992) reported a significant positive correlation between the urinary excretion of enterolactone and

total lignans with plasma SHBG in 30 postmenopausal women. In agreement with this study, we observed a moderate positive correlation between serum enterolactone and serum SHBG. Although it

is therefore possible that lignans increase SHBG levels, this effect did not translate into a reduction in risk of breast cancer in our study. Phyto-oestrogens could also affect the risk of

breast cancer in premenopausal women through changes in the menstrual cycle length. Longer cycles have been shown to be associated with a reduced risk (Olsson et al, 1983; LaVecchia et al,

1985), as would be expected under the hypothesis that cumulative frequency of ovulatory cycles is a primary determinant of risk (Henderson et al, 1985). Both daily supplementation with 10 g

of flaxseed, which is very rich in lignans (Phipps et al, 1993), and a diet rich in soy protein (Cassidy et al, 1994), a source of isoflavones, have been reported to increase the length of

the menstrual cycle, although not in all studies (Wu et al, 2000; Maskarinec et al, 2002). However, whereas this increase appeared to be due to an increase in follicular phase length in the

case of the soy protein diet (Cassidy et al, 1994), flaxseed supplementation was associated with an increase in luteal phase length (Phipps et al., 1993). As breast cell division is low

during the follicular phase but high during the luteal phase with a peak at days 23–25 (Masters et al, 1977; Meyer, 1977; Ferguson and Anderson, 1981; Going et al, 1988; Potten et al, 1988),

an increase in length of the luteal phase could contribute to an increase in risk of breast cancer. Such a mechanism would be consistent with our results as well as those of the den

Tonkelaar study (2001). However, these diet supplementation studies were small in size and their results should be regarded as preliminary. In addition, it is not clear that the generally

moderate biological levels of enterolactone in both our study and the den Tonkelaar study would have a noticeable impact on menstrual cycle length. Circulating levels of enterolactone

following flaxseed supplementation are likely to be much higher than in our study (Morton et al, 1994; Tarpila et al, 2002). In three of the prospective studies, an increase of breast cancer

risk was observed at high levels of enterolactone, although the results were not significant in the Dutch study and only marginally significant in our study. These results suggest a need

for further studies, both experimental and epidemiological, to better understand the overall impact of lignans in general, and enterolactone in particular, on the development of breast

cancer. It also suggests caution against large dietary intake of flaxseed or use of flaxseed supplements for prevention: flaxseed is the oilseed with the richest amount of lignan precursors,

and flaxseed supplementation can more than double serum enterolactone concentration (Tarpila et al, 2002). CHANGE HISTORY * _ 16 NOVEMBER 2011 This paper was modified 12 months after

initial publication to switch to Creative Commons licence terms, as noted at publication _ REFERENCES * Adlercreutz H, Mazur W (1997) Phyto-oestrogens and western diseases. _Ann Med_ 29:

95–120 Article  CAS  Google Scholar  * Adlercreutz H (1990) Western diet and western diseases: some hormonal and biochemical mechanisms and associations. _Scand J Clin Lab Invest_

50(Supplement 201): 3–23 Article  Google Scholar  * Adlercreutz H (1998) Evolution, nutrition, intestinal microflora, and prevention of cancer: a hypothesis. _Proc Soc Exp Biol Med_ 217:

241–246 Article  CAS  Google Scholar  * Adlercreutz H, Bannwart C, Wähälä K, Mäkelä T, Brunow G, Hase T, Arosemena PJ, Kellis JT, Vickery LE (1993) Inhibition of human aromatase by mammalian

lignans and isoflavonoid phytoestrogens. _J Steroid Biochem Mol Biol_ 44: 147–153 Article  CAS  Google Scholar  * Adlercreutz H, Fotsis T, Bannwart C, Wähälä K, Mäkelä T, Brunow G, Hase T

(1986) Determination of urinary lignans and phytoestrogen metabolites, potential antiestrogens and anticarcinogens, in urine of women on various habitual diets. _J Steroid Biochem_ 25:

791–797 Article  CAS  Google Scholar  * Adlercreutz H, Fotsis T, Heikkinen R, Dwyer J, Woods M, Goldin BR, Gorbach SL (1982) Excretion of the lignans enterolactone and enterodiol and of

equol in omnivorous and vegetarian postmenopausal women and in women with breast cancer. _Lancet_ 2: 1295–1299 Article  CAS  Google Scholar  * Adlercreutz H, Höckerstedt K, Bannwart C,

Bloigu S, Hämäläinen E, Fotsis T, Ollus A (1987) Effect of dietary components including lignans and phytoestrogens, on enterohepatic circulation and liver metabolism of estrogens and on sex

hormone binding globulin (SHBG). _J Steroid Biochem_ 27: 1135–1144 Article  CAS  Google Scholar  * Adlercreutz H, Mousavi Y, Clark J, Höckerstedt K, Hämäläinen E, Wähälä K, Mäkelä T, Hase T

(1992) Dietary phytoestrogens and cancer: _in vitro_ and _in vivo_ studies. _J Steroid Biochem Mol Biol_ 41: 331–337 Article  CAS  Google Scholar  * Adlercreutz H, Wang G, Lapcík O, Hampl R,

Wähälä K, Mäkelä K, Lusa K, Talme M, Mikola H (1998) Time-resolved fluorimmunoassay for plasma enterolactone. _Anal Biochem_ 265: 208–215 Article  CAS  Google Scholar  * Block G, Hartman A,

Dresser C, Carroll M, Gannon J, Gardner L (1986) A data-based approach to diet questionnaire design and testing. _Am J Epidemiol_ 124: 453–469 Article  CAS  Google Scholar  * Block G, Woods

M, Potosky A, Clifford C (1990) Validation of a self-administered diet history questionnaire using multiple diet records. _J Clin Epidemiol_ 43: 1327–1335 Article  CAS  Google Scholar  *

Borriello SP, Setchell KD, Axelson M, Lawson AM (1985) Production and metabolism of lignans by the human faecal flora. _J Appl Bacteriol_ 58: 37–43 Article  CAS  Google Scholar  * Breslow

NE, Day NE (1980) _Statistical Methods in Cancer Research_, Vol 1. International Agency for Research on Cancer: Lyon Google Scholar  * Cassidy A, Bingham S, Setchell KD (1994) Biological

effects of a diet of soy protein rich in isoflavones on the menstrual cycle of premenopausal women. _Am J Clin Nutr_ 60: 333–340 Article  CAS  Google Scholar  * Dai Q, Franke AA, Jin F, Shu

XO, Hebert JR, Custer LJ, Cheng J, Gao YT, Zheng W (2002) Urinary excretion of phytoestrogens and risk of breast cancer among Chinese women in Shanghai. _Cancer Epidemiol Biomarkers Prev_

11: 815–821 CAS  Google Scholar  * den Tonkelaar I, Keinan-Boker L, Van't Veer P, Arts CJM, Adlercreutz H, Thijssen JHH, Peeters PHM (2001) Urinary phytoestrogens and postmenopausal

breast cancer risk. _Cancer Epidemiol Biomarkers Prev_ 10: 223–228 CAS  Google Scholar  * Ferguson DJP, Anderson TJ (1981) Morphologic evaluation of cell turnover in relation to the

menstrual cycle in the ‘resting’ human breast. _Br J Cancer_ 44: 177–181 Article  CAS  Google Scholar  * Going JJ, Anderson TJ, Battersby S, MacIntyre CC (1988) Proliferative and secretory

activity in human breast during natural and artificial menstrual cycles. _Am J Pathol_ 130: 193–204 CAS  PubMed  PubMed Central  Google Scholar  * Henderson BE, Ross RK, Judd H, Krailo M,

Pike MC (1985) Do regular ovulatory cycles increase breast cancer risk? _Cancer_ 1206–1208 * Horner NK, Kristal AR, Prunti J, Skor HE, Potter JD, Lampe JW (2002) Dietary determinants of

plasma enterolactone. _Cancer Epidemiol Biomarkers Prev_ 11: 121–126 CAS  PubMed  Google Scholar  * Horn-Ross PL, John EM, Lee M, Stewart SL, Koo J, Sakoda LC, Shiau AC, Goldstein J, Davis

P, Perez-Stable EJ (2001) Phytoestrogen consumption and breast cancer risk in a multiethnic population. _Am J Epidemiol_ 154: 434–441 Article  CAS  Google Scholar  * Horn-Ross P, Barnes S,

Lee M, Coward L, Mandel JE, Koo J, John EM, Smith M (2000) Assessing phytoestrogen exposure in epidemiologic studies: development of a database (United States). _Cancer Causes Control_ 11:

289–298 Article  CAS  Google Scholar  * Hultén K, Winkvist A, Lenner P, Johansson R, Adlercreutz H, Hallmans G (2002) An incident case-referent study on plasma enterolactone and breast

cancer risk. _Eur J Nutr_ 41: 168–176 Article  Google Scholar  * Ingram D, Sanders K, Kolybaba M, Lopez D (1997) Case–control study of phyto-oestrogens and breast cancer. _Lancet_ 350:

990–994 Article  CAS  Google Scholar  * Kato I, Toniolo P, Koenig K, Kahn A, Schymura M, Zeleniuch-Jacquotte A (1999) Comparison of active and cancer registry-based follow-up for breast

cancer in a prospective cohort study. _Am J Epidemiol_ 149: 372–378 Article  CAS  Google Scholar  * Kelsey JL, Whittemore AS, Evans AS, Thompson WD (1996) _Methods in Observational

Epidemiology_. Oxford University Press: New York, Oxford Google Scholar  * Kiely M, Faughnan M, Wahala K, Brants H, Mulligan A (2003) Phyto-oestrogen levels in foods: the design and

construction of the VENUS database. _Br J Nutr_ 89(Suppl 1): S19–S23 CAS  PubMed  Google Scholar  * Kilkkinen A, Pietinen P, Klaukka T, Virtamo J, Korhonen P, Adlercreutz H (2002) Use of

oral antimicrobials decreases serum enterolactone concentration. _Am J Epidemiol_ 155: 472–477 Article  Google Scholar  * Kilkkinen A, Valsta LM, Virtamo J, Stumpf K, Adlercreutz H, Pietinen

P (2003) Intake of lignans is associated with serum enterolactone concentration in Finnish men and women. _J Nutr_ 133: 1830–1833 Article  CAS  Google Scholar  * Kilkkinen A, Virtamo J,

Vartiainen E, Sankila R, Virtanen MJ, Adlercreutz H, Pietinen P (2004) Serum enterolactone concentration is not associated with breast cancer risk in a nested case–control study. _Int J

Cancer_ 108: 277–280 Article  CAS  Google Scholar  * Kitts DD, Yuan J-M, Wijewickreme AN, Thompsom LU (1999) Antioxidant activity of the flaxseed lignan secoisolariciresinol diglycoside and

its mammalian lignan metabolites enterodiol and enterolactone. _Mol Cell Biochem_ 202: 91–100 Article  CAS  Google Scholar  * Kurzer MS, Xu X (1997) Dietary phytoestrogens. _Annu Rev Nutr_

17: 353–381 Article  CAS  Google Scholar  * LaVecchia C, Decarli A, di Pietro S, Franceschi S, Negri E, Parazzini F (1985) Menstrual cycle patterns and the risk of breast disease. _Eur J

Cancer Clin Oncol_ 21: 417–422 Article  CAS  Google Scholar  * Liang IK, Zeger SL (1986) Longitudinal data analysis using generalized linear models. _Biometrika_ 73: 13–22 Article  Google

Scholar  * Martin PM, Horwitz KB, Ryan DS, McGuire WL (1978) Phytoestrogen interaction with estrogen receptors in human breast cancer cells. _Endocrinology_ 103: 1860–1867 Article  CAS 

Google Scholar  * Maskarinec G, Williams AE, Inouye JS, Stanczyk FZ, Franke A (2002) A randomized isoflavone intervention among premenopausal women. _Cancer Epidemiol Biomarkers Prev_ 11:

195–201 CAS  PubMed  Google Scholar  * Masters JRW, Drife JO, Scarisbrick JJ (1977) Cyclic variations of DNA synthesis in human breast epithelium. _J Natl Cancer Inst_ 58: 1263–1265 Article

  CAS  Google Scholar  * Mazur W (1998) Phytoestrogen content in foods. _Baillieres Clin Endocrinol Metab_ 12: 729–742 Article  CAS  Google Scholar  * Meyer JS (1977) Cell proliferation in

normal human breast ducts, fibroadenomas, and other duct hyperplasias, measured by nuclear labeling with tritiated thymidine. _Hum Pathol_ 8: 67–81 Article  CAS  Google Scholar  * Morton MS,

Wilcox G, Wahlqvist ML, Griffiths K (1994) Determination of lignans and isoflavonoids in human female plasma following dietary supplementation. _J Endocrinol_ 142: 251–259 Article  CAS 

Google Scholar  * Olsson H, Landin-Olsson M, Gullberg B (1983) Retrospective assessment of menstrual cycle length in patients with breast cancer, in patients with benign breast disease, and

in women without breast disease. _J Natl Cancer Inst_ 70: 17–20 CAS  PubMed  Google Scholar  * Peeters PHM, Keinan-Boker L, van der Schouw YT, Grobbee DE (2003) Phytoestrogens and breast

cancer risk. Review of the epidemiological evidence. _Breast Cancer Res Treat_ 77: 171–183 Article  CAS  Google Scholar  * Phipps WR, Martini MC, Lampe JW, Slavin JL, Kurzer M (1993) Effect

of flax seed ingestion on the menstrual cycle. _J Clin Endocrinol Metab_ 77: 1215–1219 CAS  PubMed  Google Scholar  * Pietinen P, Stumpf K, Männistö S, Kataja V, Uusitupa M, Adlercreutz M

(2001) Serum enterolactone and risk of breast cancer: a case–control study in Eastern Finland. _Cancer Epidemiol Biomarkers Prev_ 10: 339–344 CAS  PubMed  Google Scholar  * Potten CS, Watson

RJ, Williams GT, Tickle S, Roberts SA, Harris M, Howell A (1988) The effect of age and menstrual cycle upon proliferative activity of the normal human breast. _Br J Cancer_ 58: 163–170

Article  CAS  Google Scholar  * Robins J, Gail MH, Lubin JH (1986) More on ‘Biased selection of controls for case–control analyses of cohort studies’. _Biometrics_ 42: 293–299 Article  CAS 

Google Scholar  * Rose DP (1992) Dietary fiber, phytoestrogens, and breast cancer. _Nutrition_ 8: 47–51 CAS  PubMed  Google Scholar  * Saarinen N, Huovinen R, Warri A, Makela S,

Valentin-Blasini L, Sjoholm R, Ammala J, Lehtila R, Eckerman C, Collan Y, Santti RS (2002) Enterolactone inhibits the growth of 7,12-dimethylbenz(a)anthracene-induced mammary carcinomas in

the rat. _Mol Cancer Ther_ 1: 869–876 CAS  PubMed  Google Scholar  * Setchell KD, Lawson AM, Borriello SP, Harkness R, Gordon H, Morgan DML, Kirk DN, Adlercreutz H, Anderson LC, Axelson M

(1981) Lignan formation in man-microbial involvement and possible roles in relation to cancer. _Lancet_ 2: 4–7 Article  CAS  Google Scholar  * Stumpf K, Uehara M, Nurmi T, Adlercreutz H

(2001) Changes in the time-resolved fluoroimmunoassay of plasma enterolactone. _Anal Biochem_ 284: 153–157 Article  Google Scholar  * Tarpila S, Aro A, Salminen I, Tarpila A, Kleemola P,

Akkika J, Adlercreutz H (2002) The effect of flaxseed supplementation in processed foods on serum fatty acids and enterolactone. _Eur J Clin Nutr_ 56: 157–165 Article  CAS  Google Scholar  *

Thompson LU, Robb P, Serraino M, Cheung F (1991) Mammalian lignan production from various foods. _Nutr Cancer_ 16: 43–52 Article  CAS  Google Scholar  * Toniolo PG, Pasternack BS, Shore RE,

Sonnenschein EG, Koenig KL, Rosenberg C, Strax P, Strax S (1991) Endogenous hormones and breast cancer: a prospective cohort study. _Breast Cancer Res Treat_ 18: S23–S26 Article  Google

Scholar  * Toniolo P, Levitz M, Zeleniuch-Jacquotte A, Banerjee S, Koenig KL, Shore RE, Strax P, Pasternack BS (1995) A prospective study of endogenous estrogens and breast cancer in

postmenopausal women. _J Natl Cancer Inst_ 87: 190–197 Article  CAS  Google Scholar  * Valsta LM, Kilkkinen A, Mazur W, Nurmi T, Lampi AM, Ovaskainen ML, Korhonen T, Adlercreutz H, Pietinen

P (2003) Phyto-oestrogen database of foods and average intake in Finland. _Br J Nutr_ 89(Suppl 1): S32–S38 Google Scholar  * Wang C, Mäkelä T, Hase T, Adlercreutz H, Kurzer M (1994) Lignans

and flavonoids inhibit aromatase enzyme in human preadipocytes. _J Steroid Biochem Mol Biol_ 50: 205–212 Article  CAS  Google Scholar  * Wu AH, Stanczyck FZ, Hendrich S, Murphy PA, Zhang C,

Wan P, Pike MC (2000) Effects of soy foods on ovarian function in premenopausal women. _Br J Cancer_ 82: 1879–1886 Article  CAS  Google Scholar  * Zeleniuch-Jacquotte A, Adlercreutz H,

Akhmedkhanov A, Toniolo P (1998) Reliability of serum measurements of lignans and isoflavonoid phytoestrogens over a two-year period. _Cancer Epidemiol Biomarkers Prev_ 7: 885–889 CAS 

PubMed  Google Scholar  * Zeleniuch-Jacquotte A, Shore RE, Koenig KL, Akhmedkhanov A, Afanasyeva Y, Kato I, Kim MY, Rinaldi S, Kaaks R, Toniolo P (2004) Postmenopausal levels of estrogen,

androgen, and SHBG and breast cancer risk: long-term results of a prospective study. _Br J Cancer_ 90: 153–159 Article  CAS  Google Scholar  Download references ACKNOWLEDGEMENTS This work

was supported by American Cancer Society grant RPG-98-333-01-CCE, National Cancer Institute grant CA34588 and center grant CA16087, and National Institute of Environmental Health Sciences

center grant P30 ES-00260. We thank Yelena Afanasyeva, Jo-Ann Cutrone, Daniela Masciangelo and Lynne Quinones for technical assistance. AUTHOR INFORMATION AUTHORS AND AFFILIATIONS *

Department of Environmental Medicine, New York University School of Medicine, 650 First Avenue, Room 539, New York, 10016, NY, USA A Zeleniuch-Jacquotte, R E Shore, K L Koenig, A A Arslan 

& P Toniolo * New York University Cancer Institute, New York University School of Medicine, New York, 10016, NY, USA A Zeleniuch-Jacquotte, R E Shore, K L Koenig, A A Arslan & P

Toniolo * Folkhälsan Research Center and Department of Clinical Chemistry, Institute for Preventive Medicine, Nutrition and Cancer, University of Helsinki, POB 63, FIN-00014, Finland H

Adlercreutz * Department of Pathology, Karmanos Cancer Institute, Wayne State University, 110 E Warren Ave., Detroit, 48201, MI, USA I Kato * Department of Obstetrics and Gynecology, New

York University School of Medicine, New York, 550 First Avenue NB9E2, New York, 10016, NY, USA A A Arslan & P Toniolo Authors * A Zeleniuch-Jacquotte View author publications You can

also search for this author inPubMed Google Scholar * H Adlercreutz View author publications You can also search for this author inPubMed Google Scholar * R E Shore View author publications

You can also search for this author inPubMed Google Scholar * K L Koenig View author publications You can also search for this author inPubMed Google Scholar * I Kato View author

publications You can also search for this author inPubMed Google Scholar * A A Arslan View author publications You can also search for this author inPubMed Google Scholar * P Toniolo View

author publications You can also search for this author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to A Zeleniuch-Jacquotte. RIGHTS AND PERMISSIONS From twelve months after

its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit

http://creativecommons.org/licenses/by-nc-sa/3.0/ Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Zeleniuch-Jacquotte, A., Adlercreutz, H., Shore, R. _et al._ Circulating

enterolactone and risk of breast cancer: a prospective study in New York. _Br J Cancer_ 91, 99–105 (2004). https://doi.org/10.1038/sj.bjc.6601893 Download citation * Received: 20 January

2004 * Revised: 29 March 2004 * Accepted: 31 March 2004 * Published: 29 June 2004 * Issue Date: 05 July 2004 * DOI: https://doi.org/10.1038/sj.bjc.6601893 SHARE THIS ARTICLE Anyone you share

the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer

Nature SharedIt content-sharing initiative KEYWORDS * breast cancer * enterolactone * lignan * phyto-oestrogen * prospective study